Today showed that capital rarely moves in one step. Kodal set a cash-funded route across West African lithium, Greece and the UAE bundled signed agreements with future investment, and global transactions split value across ownership, new money, licensing, public-market demand and contract exits.
Kodal chooses a cash-funded route for regional lithium expansion
Kodal Minerals said it plans to build a broader West African lithium portfolio beyond its producing Bougouni mine in Mali. Exploration will be funded from existing cash and mine cash flow rather than a fresh equity raise; its Ghana position is a staged earn-in signed on 19 October, not a new acquisition today.
The UAE and Greece bundle signed deals with a larger investment plan
The UAE and Greece announced 18 memoranda, agreements and commercial partnerships valued at €12.75 billion, while Abu Dhabi outlined a further €15 billion investment plan. The first figure covers announced instruments; the additional €15 billion is planned capital without disclosed individual investments.
QatarEnergy combines a signed LNG contract with separate advanced talks
QatarEnergy is in advanced talks to buy at least 3 million tonnes of LNG a year from Venture Global, with no agreement timeline disclosed. Separately, Cheniere signed a 4 million-tonne annual supply contract running from 2031 to 2054.
BASF raises the price and employment protections in its Evonik approach
BASF increased its reported Evonik offer to €24 a share, valuing the target at about €11.18 billion, and added assurances on jobs and production sites. Evonik previously rejected the earlier approach, and no accepted transaction has been announced.
Pitchwise agrees a 42% Valencia stake with fresh capital
Pitchwise Holdings agreed to acquire 42% of Valencia CF from Meriton in a transaction valuing the club at €1.25 billion including debt. The investors will add €100 million of new capital; Meriton keeps majority control and closing conditions remain.
Roche licenses Zymeworks cancer therapy through staged economics
Roche obtained global development and commercialisation rights to Zymeworks’ experimental lung-cancer therapy in a deal worth up to US$813 million. Zymeworks receives US$55 million upfront, with the balance dependent on study, development, regulatory and commercial milestones.
Jio closes its order book with demand above thirteen times
Jio Platforms’ US$3.2 billion IPO attracted more than 12 million applications and public subscriptions above thirteen times the shares offered on the final bidding day. Institutional demand reached 35 times, while trading is scheduled to begin on Wednesday.
GM terminates a strategic supply agreement and creates acquisition risk
GM cancelled its long-term supply agreement with rare-earth magnet producer VAC, prompting arbitration. VAC was expected to sell 90% of its new US plant’s capacity to GM, and the dispute may alter the price Energy Fuels agreed to pay for VAC.
What the structure tells us
Africa’s qualifying development is a next-stage decision, not a new closing. Kodal’s West African expansion has a staged Ghana earn-in behind it, but today’s news is the choice to fund regional exploration from existing cash and operating mine cash flow.
The global board makes the same distinction. A higher bid is not acceptance, a licence headline includes contingent milestones, heavy IPO demand is not yet trading performance, and a terminated supply agreement can reshape the economics of a separate acquisition.
transactions · critical minerals · investment · M&A · licensing · IPO · energy · contract risk